Assessing R&D Capacity on NTDs

Carlos M. Correa

South Centre/UNDP Workshop on Mechanisms to Increase Financing for Research and Development (R&D) for Tuberculosis (TB), Malaria and other Neglected Tropical Diseases (NTDs)
Investment in R&D

- What is the country’s investment in R&D in pharmaceuticals, particularly relating to NTDs?
- What is the relative public and private sector participation? What is the main object/purpose of locally undertaken R&D (e.g. vaccines, new synthetic drugs, improvement or new indications of existing drugs, biologicals, diagnostic tools)?
- Is there investment in R&D by foreign companies?
Patents for pharmaceuticals and specifically for NTDs

- How many patents for pharmaceuticals in general, and specifically for NTDs, have been applied for in the last XX years by local companies/individuals nationally and internationally?
- How many patents have been granted?
- Is there information about the exploitation of granted patents?
- How many patent foreign applications and grants can be found?
Do patent applications/grants relate to new chemical entities or to ‘incremental’ innovation in pharmaceuticals, e.g. new formulations, polymorphs, salts, etc.?
Projects specifically related to NTDs

- What are the objectives, level of funding, achievements of projects specifically related to NTDs?
- Which entities participate?
- Are there papers published in peer-reviewed journals?
What is the number and qualifications of R&D staff working (part- or full-time) in projects specifically related to NTDs?
In which therapeutic areas is R&D related to NTDs most relevant in terms of investment, personnel and outcomes obtained?
Government support for R&D in NTDs

- In which areas government support for R&D in relation to NTDs is focused?
- Is support limited to the research phase or it also includes testing and commercialization?
- Is funding sustainable? Is cooperation with local or foreign institutions taken place?
- What methodologies are applied to assess the performance of R&D projects?
- Have new or improved substances or products obtained from R&D activities been commercialized locally or abroad?
- Have licenses been granted and royalties been obtained from their exploitation?
What are the main obstacles to enhance local R&D on NTDS, financial, lack of personnel, etc.?
Thank you